IMMU Share Price Performance
SEK 5.18
-0.02 (-0.38%)
67.6% undervalued intrinsic discount
SEK 16.00
Fair Value
Price SEK 5.18
AnalystConsensusTarget SEK 16.00
Fair ValueSEK 16.00
Share Pricen/a
New Narrative • May 12
Mendus AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
IMMU Community Narratives
AN
Fair Value
·Fair Value SEK 16 67.6% undervalued intrinsic discount
Post Remission Myeloid Cancer Focus Will Support Future Opportunity For This Biotech
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Post Remission Myeloid Cancer Focus Will Support Future Opportunity For This Biotech
Catalysts About Mendus Mendus is a biotech company developing vididencel, an immunotherapy aimed at improving outcomes in myeloid blood cancers such as AML and CML, with a partnered ovarian cancer program. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 16
67.6% undervalued intrinsic discount
Fair Value
Profit Margin
17.72%
Future PE
72.97x
Price in 2029
SEK 0
Trending Discussion
Recently Updated Narratives
AN
Post Remission Myeloid Cancer Focus Will Support Future Opportunity For This Biotech
Fair Value: SEK 16 67.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Mendus AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 20, 2026
- -1.69
- 0%
- 0%
- 0.2%
About IMMU
- Founded
- 2002
- Employees
- 27
- CEO
- WebsiteView website
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
